BenevolentAI Investor Day Presentation Deck

Therapy area and business model rationale SCIENTIFIC COMMERCIAL CLINICAL DEVELOPMENT DATA SCIENTIFIC & BD STRATEGY CORE THERAPEUTIC AREAS IMMUNOLOGY NEUROLOGY ONCOLOGY OTHER CURRENT PIPELINE PROGRAMMES Clinical development & ANY INDICATIONS commercialisation Development & out-license at IND, Phase I or Phase II Out-license prior to Phase I NON CORE THERAPEUTIC AREAS Pharma collaborations Non-commercial collaborations Benevolent 21

View entire presentation